Topical steroids do not downregulate expression of growth-related oncogene-α in nasal polyps

References

• Pawankar R. Nasal polyposis: an update. Curr Opin Allergy Clin Immunol 2003; 3: 1–6
   PubMedGoogle Scholar
• Holmström M, Holmberg K, Lundblad L, Norlander T, Stierna P. Current perspectives on the treatment of nasal polyposis: a Swedish opinion report. Acta Otolaryngol 2002; 122: 736–44
   PubMed Web of Science ®Google Scholar
• Hamilos DL, Thawley SE, Kramper MA, Kamil A, Hamid QA. Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression and proinflammatory cytokine mRNA in nasal polyp disease. J Allergy Clin Immunol 1999; 103: 79–87
   PubMedGoogle Scholar
• Molet SM, Hamid QA, Hamilos DA. IL-11 and IL-17 expression in nasal polyps: relationship to collagen deposition and suppression by intranasal fluticasone proprionate. Laryngoscope 2003; 113: 1803–12
   PubMed Web of Science ®Google Scholar
• Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001; 250: 91–104
   PubMed Web of Science ®Google Scholar
• Richmond A, Thomas HG. Purification of melanoma growth stimulatory activity. J Cell Physiol 1986; 129: 375–84
   PubMed Web of Science ®Google Scholar
• Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity. J Immunol 2000; 165: 5269–77
   PubMed Web of Science ®Google Scholar
• Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. Neutrophil-activating properties of the melanoma growth-stimulatory activity. J Exp Med 1990; 171: 1797–802
   PubMed Web of Science ®Google Scholar
• Klein AM, Anderson K, Lafreniere D, Leonard G, Kreutzer D. Growth-related oncogene-alpha expression in human nasal polyps. Otolaryngol Head Neck Surg 2000; 123: 85–90
   PubMedGoogle Scholar
• Bjartell A, Malm J, Möller C, Gunnarsson M, Lundwell A, Lilja H. Distribution and tissue expression of semenogelin I and II in man as demonstrated by in situ hybridization and immunocytochemistry. J Androl 1996; 17: 17–26
   PubMedGoogle Scholar
• Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219–29
   PubMed Web of Science ®Google Scholar
• Wen DZ, Rowland A, Derynck R. Expression and secretion of gro/MGSA by stimulated human endothelial cells. EMBO J 1989; 8: 1761–6
   PubMed Web of Science ®Google Scholar
• Benson M, Strannegard IL, Strannegard O, Wennergren G. Topical steroid treatment of allergic rhinitis decreases nasal fluid TH2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-gamma, IL-1β, TNF-α, or neutrophils. J Allergy Clin Immunol 2000; 106: 307–12
   PubMed Web of Science ®Google Scholar
• Saklatvala J, Dean J, Clark A. Control of the expression of inflammatory response genes. Biochem Soc Symp 2003; 70: 95–106
   PubMed Web of Science ®Google Scholar
• Nonaka R, Nonaka M, Takanashi S, Jordana M, Dolovich J. Eosinophil activation in the tissue: synthetic steroid, budesonide, effectively inhibits the survival of eosinophils isolated from peripheral blood but not nasal polyp tissues. J Clin Lab Immunol 1999; 51: 39–53
   PubMedGoogle Scholar
• Hamilos DL, Leung DY, Muro S, Kahn AM, Hamilos SS, Thawley SE, et al. GRbeta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone. J Allergy Clin Immunol 2001; 108: 59–68
   PubMed Web of Science ®Google Scholar
• Elovic A, Wong DT, Weller PF, Matossian K, Galli SJ. Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. J Allergy Clin Immunol 1994; 93: 864–9
   PubMed Web of Science ®Google Scholar
• Persson-Dajotoy T, Andersson P, Bjartell A, Calafat J, Egesten A. Expression and production of the CXC chemokine growth-related oncogene-alpha by human eosinophils. J Immunol 2003; 170: 5309–16
   PubMedGoogle Scholar
• Oakley CM, Olsen EGJ. Eosinophilia and heart disease. Br Heart J 1977; 39: 233–7
   PubMedGoogle Scholar
• Roche WR, Williams JH, Beasley R, Holgate ST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989; 1: 520–3
   PubMed Web of Science ®Google Scholar
• Podolin PL, Bolognese BJ, Foley JJ, Schmidt DB, Buckley PT, Widdowson KL, et al. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol 2002; 169: 6435–44
   PubMed Web of Science ®Google Scholar